Shereif H Rezkalla

List of Publications by Year
in descending order

27 papers	1,672 citations	567281 15 h-index	642732 23 g-index
27 all docs	27 docs citations	27 times ranked	2218 citing authors

#	Article	IF	Citations
1	ST Segment Elevation Myocardial Infarction in the COVID-19 Era: Appraisal of the Evidence. Clinical Medicine and Research, 2022, 20, 52-60.	0.8	0
2	Author Response to â€œAspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease and Colorectal Carcinomasâ€• Clinical Medicine and Research, 2021, 19, 1.2-2.	0.8	0
3	Viral myocarditis: 1917â€“2020: From the Influenza A to the COVID-19 pandemics. Trends in Cardiovascular Medicine, 2021, 31, 163-169.	4.9	46
4	Post-Acute Sequelae of SARS-COVID-2 Syndrome: Just the Beginning. Cardiology Research, 2021, 12, 279-285.	1.1	3
5	Aspirin in Primary Prevention of Cardiovascular Events. Clinical Medicine and Research, 2020, 18, 89-94.	0.8	10
6	Management of No-Reflow Phenomenon in the Catheterization Laboratory. JACC: Cardiovascular Interventions, 2017, 10, 215-223.	2.9	160
7	Cardiovascular consequences of cocaine use. Trends in Cardiovascular Medicine, 2015, 25, 517-526.	4.9	74
8	Aspirin overutilization for the primary prevention of cardiovascular disease. Clinical Epidemiology, 2014, 6, 433.	3.0	18
9	The Role of Aspirin in the Prevention of Cardiovascular Disease. Clinical Medicine and Research, 2014, 12, 147-154.	0.8	146
10	Noâ€Reflow Phenomenon Following Percutaneous Coronary Intervention for Acute Myocardial Infarction: Incidence, Outcome, and Effect of Pharmacologic Therapy. Journal of Interventional Cardiology, 2010, 23, 429-436.	1.2	124
11	Influenza-related viral myocarditis. Wisconsin Medical Journal, 2010, 109, 209-13.	0.3	21
12	Coronary noâ€reflow phenomenon: From the experimental laboratory to the cardiac catheterization laboratory. Catheterization and Cardiovascular Interventions, 2008, 72, 950-957.	1.7	192
13	Cocaine-Induced Acute Myocardial Infarction. Clinical Medicine and Research, 2007, 5, 172-176.	0.8	65
14	Preconditioning in humans. Heart Failure Reviews, 2007, 12, 201-206.	3.9	38
15	Management strategies for ST-elevation myocardial infarction in the emergency department. Wisconsin Medical Journal, 2007, 106, 219-24.	0.3	0
16	Lipid-Rich Plaque Masquerading as a Coronary Thrombus. Clinical Medicine and Research, 2006, 4, 119-122.	0.8	1
17	Ischemic preconditioning for the clinician. Wisconsin Medical Journal, 2006, 105, 22-6.	0.3	0
18	Coronary no-reflow phenomenon. Current Treatment Options in Cardiovascular Medicine, 2005, 7, 75-80.	0.9	18

#	Article	IF	Citations
19	Ischemic preconditioning and preinfarction angina in the clinical arena. Nature Clinical Practice Cardiovascular Medicine, 2004, 1, 96-102.	3.3	72
20	Effectiveness of acetylcysteine on preventing renal dysfunction in patients undergoing coronary procedures. Wisconsin Medical Journal, 2004, 103, 38-41.	0.3	1
21	Eptifibatide-induced acute profound thrombocytopenia presenting as refractory hypotension. Catheterization and Cardiovascular Interventions, 2003, 58, 76-79.	1.7	31
22	Coronary no-flow and ventricular tachycardia associated with habitual marijuana use. Annals of Emergency Medicine, 2003, 42, 365-369.	0.6	101
23	Successful Direct Stenting Guided by Intravascular Ultrasound without Contrast in a Patient with Renal Dysfunction. Journal of Interventional Cardiology, 2003, 16, 449-451.	1.2	3
24	Contrast Nephropathy. Clinical Medicine and Research, 2003, 1, 301-304.	0.8	5
25	Antiplatelet Therapy from Clinical Trials to Clinical Practice. Clinical Medicine and Research, 2003, 1, 101-104.	0.8	9
26	No-Reflow Phenomenon. Circulation, 2002, 105, 656-662.	1.6	530
27	Myocardial infarction temporally related to ephedra--a possible role for the coronary microcirculation. Wisconsin Medical Journal, 2002, 101, 64-6.	0.3	4